Trial: 202104039

Phase I/II study exploring the safety and efficacy of combining APL-101 with frontline osimertinib in patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC)

Phase

I/II

Principal Investigator

Devarakonda, Siddhartha

Disease Site

Lung; Lung Cancer – Non-small Cell

Learn more about this study at: clinicaltrials.gov